Patient-Centric & Prospective Medicine Project

The Center for Medicine in the Public Interest (CMPI) has initiated a research program to study the treatment preferences of patients with Idiopathic pulmonary fibrosis (IPF). The project is supported by Intermune, a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Dr. John F P Bridges PhD, an Associate Professor at the Johns Hopkins Bloomberg School of Public Health and Senior Fellow at CMPI, will serve as the principal investigator of this project. The project will apply the principles of community-based participatory medicine to engage patients, family members, providers and other stakeholder in the design and pilot of a survey instrument to measure the stated-preferences of patients of with IPF for the potential benefits and risk of therapy. A geographically diverse sample of patients with IPF will be then recruited through clinics and advocacy groups to complete the survey. Analysis will use state-of-the-art methods to estimate preferences and results will be disseminated widely.
Sign Up for Our Email Newsletter

RECENT NEWS

Concerns Arise Over Protests During Coronavirus Pandemic

Concerns Arise Over Protests During Coronavirus Pandemic

Peter Pitts appears on NBC 6 Miami with Sheli Muñiz to discuss the protests and spread of coronavirus...  Read more

$40 price tag for potential coronavirus vaccine seems to be ‘right on the money,’ says think tank

$40 price tag for potential coronavirus vaccine seems to be ‘right on the money,’ says think tank

If a potential coronavirus vaccine is not affordable, too many people will not get vaccinated, says Peter Pitts, presiden...  Read more

Early success of COVID-19 vaccine candidates fuels optimism, but experts warn 'a lot has to go right'

Early success of COVID-19 vaccine candidates fuels optimism, but experts warn 'a lot has to go right'

USA TODAY created a panel of experts to estimate how far we are from when a COVID-19 vaccine will be available to all Ame...  Read more

DRUGWONKS BLOG